Amendments to the Claims:

Please amend claims 20 and 37. This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-19. (Canceled)

20. (Currently amended) A method of assessing potential susceptibility to development of Acute Life Threatening Episodes (ALTE) and/or Sudden Infant Death Syndrome (SIDS) in a subject including:

(a) determination of the immunoglobulin A (IgA) level in a sample from the subject; and

(b) prediction of susceptibility to development of ALTE and/or SIDS by comparison of said IgA level with a predetermined standard.

21. (Previously presented) A method of assessing potential susceptibility to development of Acute Life Threatening Episodes (ALTE) and/or Sudden Infant Death Syndrome (SIDS) in a subject including:

(a) determination of immunoglobulin A1 (IgA1) level in a sample from the subject; and

(b) prediction of susceptibility to development of ALTE and/or SIDS by comparison of said IgA1 level with a predetermined standard.

22. (Previously presented) A method according to claim 20 or claim 21 wherein the subject is a human infant.

23. (Previously presented) A method according to claim 20 or claim 21 wherein the sample is a sample from a subject at the time of, or any time up to approximately 2 weeks after, an upper respiratory tract infection (URTI) and/or symptoms.

24. (Previously presented) A method according to claim 20 or claim 21 wherein the immunoglobulin is secretory immunoglobulin.

25. (Previously presented) A method according to claim 20 or claim 21 wherein the immunoglobulin is salivary immunoglobulin.

26. (Previously presented) A method according to claim 20 or claim 21 wherein the sample is whole unstimulated saliva.

27. (Previously presented) A method according to claim 20 or claim 21 wherein the subject is not fasting when the sample is collected.

28. (Previously presented) A method according to claim 20 or claim 21 wherein the immunoglobulin level is determined by Enzyme Linked Immunosorbent Assay (ELISA).

29. (Previously presented) A method according to claim 20 or claim 21 wherein the immunoglobulin level is determined by radial immunodiffusion.

30. (Previously presented) A method according to claim 20 or claim 21 wherein the immunoglobulin level is analysed by a rapid near-subject assay.

31. (Previously presented) A method according to claim 20 or claim 21 wherein the immunoglobulin level is determined by contacting a body secretion with an assay device or system on a support.

32. (Previously presented) A method according to claim 20 or claim 21 wherein the immunoglobulin level is analysed by contacting an assay device or system with the saliva of the subject *in situ*.

33. (Previously presented) A method according to claim 20 or claim 21 wherein the standard is a normal population standard.

34. (Previously presented) A method according to claim 20 or claim 21 wherein the standard is an internal personal standard.

35. (Canceled)

36. (Previously presented) A method according to claim 21 further including comparison of the ratio of immunoglobulin level to indicators relating to any one or more of: IgM, IgG, and acute phase reactants.

37. (Currently amended) A method for assessing potential susceptibility to development of Acute Life Threatening Episodes (ALTE) and/or Sudden Infant Death Syndrome (SIDS) in an infant including:

(a) determination of the immunoglobulin A (IgA) and/or immunoglobulin A1 (IgA1) level in a sample of the infant's whole, unstimulated saliva; and

(b) prediction of susceptibility to development of ALTE and/or SIDS by comparison of said IgA and/or said IgA1 level with a predetermined standard.

38. (Previously presented) A kit when used in a method according to any one of claims 20, 21 or 37.

39. (Previously presented) A methods of measuring immune function in children comprising:

(a) determination of the immunoglobulin A (IgA) level in a sample from this subject; and

(b) comparison of said IgA level with a predetermined standard.